ArticleNature biomedical engineering2025
Small circular RNAs as vaccines for cancer immunotherapy.
Erratum issuedAbstract read
In one paragraph
Article in Nature biomedical engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Emerging strategies and innovations in circular RNA synthesis.Molecular therapy. Nucleic acids · 2026Review
- Bioengineering strategies for improving the immunogenicity of mRNA vaccines.Signal transduction and targeted therapy · 2026Review
- Engineering circular RNA expression systems to minimize contaminating linear RNA byproducts.bioRxiv : the preprint server for biology · 2026Article
- Research Progress, Application, and Industrialization Prospects of Circular RNA Vaccines in Viral Diseases.Vaccines · 2026Review
- Therapeutic vaccines for NSCLC: From mechanisms to clinical translation.Chinese medical journal pulmonary and critical care medicine · 2026Review
- Overcoming Drug Resistance by Paclitaxel Resistance in Triple-Negative Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- IVT-free, chemically synthesized protein-encoding RNA oligonucleotides for rapid production of personalized cancer vaccines.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Engineered circular RNA compatible with complete nucleoside modification and rolling circle translation through a Cap-independent translation enhancer.Nature biomedical engineering · 2026Article
- Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancer.Nature cancer · 2026Article
- Lipid nanoparticle delivery of circle RNA vaccine induces potent immune responses.Scientific reports · 2026Article
- Beyond conceptual advances in cancer therapies.Nature biomedical engineering · 2026Article
- Circular RNA as a New Vaccine Platform: Considerations, Challenges, and Perspectives.Vaccines · 2026Review
- Biomimetic liposomes in drug delivery: from design mechanisms to applications.Chemical Society reviews · 2026Review
- RNA-Based Therapeutic Strategies in Multiple Myeloma: From Molecular Targets to Delivery and Clinical Translation.International journal of molecular sciences · 2026Review
- Circular RNA-based HPV16 therapeutic vaccine elicits potent and durable antitumor immunity.Journal of experimental & clinical cancer research : CR · 2026Article
- CIRCpedia v3: an interactive database for circular RNA characterization and functional exploration.Nucleic acids research · 2026Article
- Review
- Circular RNA therapeutics: a new class of long-acting RNA medicines for oncology, immunology, and rare diseases.Frontiers in immunology · 2026Review
- Autophagy-Modulated Sonodynamic Therapy Triggers Mitochondrial Catastrophe for Potent Immunogenic Tumor Eradication.Biomaterials research · 2026Article
- Review
Corrections and comments
- Erratum issued
Authors and funding
19 authors.
Yu Zhang *Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Xiang Liu *Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Tingting ShenThe Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Qiyan WangDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0001-6379-7879
Shurong ZhouDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Suling YangDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Shimiao LiaoDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Ting SuCollege of Biological Science and Medical Engineering, Donghua University, Shanghai, China.
Lei MeiDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Bei ZhangDepartment of Biostatistics, School of Medicine; Bioinformatics Shared Resource, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Khoa HuynhDepartment of Biostatistics, School of Medicine; Bioinformatics Shared Resource, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Linying XieGenomics Core, Virginia Commonwealth University, Richmond, VA, USA.
Youzhong GuoDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA.ORCID http://orcid.org/0000-0001-7177-9603
Chunqing GuoDepartment of Human and Molecular Genetics and Institute of Molecular Medicine, School of Medicine; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Katarzyna M TycDepartment of Biostatistics, School of Medicine; Bioinformatics Shared Resource, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Xufeng QuDepartment of Biostatistics, School of Medicine; Bioinformatics Shared Resource, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Xiang-Yang WangDepartment of Human and Molecular Genetics and Institute of Molecular Medicine, School of Medicine; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Jinze LiuDepartment of Biostatistics, School of Medicine; Bioinformatics Shared Resource, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Guizhi ZhuDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA. guizhiz@med.umich.edu.ORCID http://orcid.org/0000-0002-2945-7982
Funding
XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2MVirus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Kim Felder Rhoads · 1985 to 2026
$51.0MResearch Supplement to Promote Diversity in Health Related ResearchUL1TR002649 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2018 to 2022
$19.1MWright Regional Center for Clinical and Translational ScienceUM1TR004360 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI FREDERICK Gerard MOELLER · 2023 to 2026
$16.3MVCU Neuroscience Center Core GrantP30NS047463 · NINDS · VIRGINIA COMMONWEALTH UNIVERSITY · PI POVLISHOCK, JOHN T · 2003 to 2013
$5.0MInstitutional Career Development CoreKL2TR002648 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI NANASINKAM, SERGE PATRICK, SANYAL, ARUN J · 2018 to 2022
$3.7MMultivalent Small Circular mRNA Vaccines for Melanoma Combination ImmunotherapyR01CA286122 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Xiang-Yang Shawn Wang, Guizhi Zhu · 2024 to 2026
$2.8MSmall Circular mRNA VaccinesR01AI168684 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI ZHU, GUIZHI · 2022 to 2025
$2.2MNucleic Acid Modulators and Theranostics for ADARR35GM143014 · NIGMS · VIRGINIA COMMONWEALTH UNIVERSITY · PI ZHU, GUIZHI · 2021 to 2025
$2.1MLymph Node-Targeted Codelivery of Albumin-Binding Peptide Antigens and Di-Adjuvant for Melanoma Combination ImmunotherapyR01CA266981 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Guizhi Zhu · 2022 to 2026
$2.0MGlioblastoma radioimmunotherapyR21NS114455 · NINDS · VIRGINIA COMMONWEALTH UNIVERSITY · PI VALERIE, KRISTOFFER CARL, ZHU, GUIZHI · 2020 to 2021
$427kAmerican Cancer Society (American Cancer Society, Inc.) RSG-22-055-01-IBCDNCATS NIH HHS KL2 TR002648NCATS NIH HHS UL1 TR002649NCATS NIH HHS UM1 TR004360NCI NIH HHS P30 CA016059NCI NIH HHS P30 CA046592NCI NIH HHS R01 CA266981NCI NIH HHS R01 CA286122NIAID NIH HHS R01 AI168684NIGMS NIH HHS R35 GM143014NINDS NIH HHS P30 NS047463NINDS NIH HHS R21 NS114455United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (CDMRP) BC210931/P1U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA266981U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI168684U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R35GM143014
Abstract
Messenger RNA vaccines have shown strong prophylactic efficacy against viral infections. Here we show that antigen-encoding small circular RNAs (circRNAs) loaded in lipid nanoparticles elicit potent and durable T cell responses for robust tumour immunotherapy after subcutaneous injection in mice, particularly when combined with immune checkpoint inhibition. The small circRNA vaccines are highly stable and show low levels of activation of protein kinase R as well as low cytotoxicity, enabling long-lasting antigen translation (longer than 1 week in cells). Relative to large protein-encoding unmodified or modified mRNAs and circRNAs, small circRNA vaccines elicited up to 10-fold antigen-specific T cells in mice and accounted for 30-75% of the total peripheral CD8
Indexed as
Cancer VaccinesImmunotherapyNeoplasmsRNA, CircularAnimalsAntigens, NeoplasmCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansMelanoma, ExperimentalMiceMice, Inbred C57BLNanoparticlesAntigens, NeoplasmCancer VaccinesRNA, Circular
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.